Ishita Drugs & Industries Ltd has scheduled its 33rd Annual General Meeting for Wednesday, September 30, 2026. The board confirmed the schedule in a filing with the Bombay Stock Exchange on August 27, 2026.

The meeting will be held at 11:30 am at "Manthan", Hotel Krsna Lila, in Sanand, Gujarat. Shareholders eligible as of the record date will be able to cast their votes electronically during the designated window.

Book Closure and Voting Schedule

The register of members and share transfer books will remain closed from September 24, 2026, to September 30, 2026, both days inclusive. This period determines eligibility for the AGM.

The company will utilize the services of National Securities Depository Limited (NSDL) for the electronic voting process. The e-voting period runs from Sunday, September 27, 2026, through Tuesday, September 29, 2026.

AGM Agenda Items

The notice outlines ordinary and special business to be transacted during the meeting.

Ordinary Business:

• Adoption of audited financial statements for FY26.
• Re-appointment of M/s Jaymin Shah & Associates as statutory auditors.
• Approval of related-party transactions with Ishita Pharmaceuticals.
• Approval of related-party transactions with Anvi Lifesciences Private Limited.

Special Business:

• Re-appointment of Mrs. Abha Agrawal as a Non-Executive Non-Independent Director post attaining the age of 75 years.

Mrs. Agrawal, a promoter associated with the company for over 30 years, retires by rotation. The board recommends her re-appointment citing her extensive experience in business matters and governance oversight.

The related-party transactions involve sales, purchases, leasing, and services with Ishita Pharmaceuticals and Anvi Lifesciences Private Limited. These entities are linked to key management personnel, including Managing Director Jagdish Agrawal and CFO Sumit Agrawal. The transactions are expected to exceed 10% of the company's annual turnover, necessitating shareholder approval under SEBI (LODR) Regulations.

Regulatory Compliance and Shareholder Communication

The intimation was issued in accordance with Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Jagdish Agrawal, Managing Director of Ishita Drugs & Industries Ltd, signed the communication.

In compliance with Regulation 36(1)(b) of the Listing Regulations, the company issued letters providing a weblink to the Annual Report and AGM Notice for shareholders who have not registered their email addresses with the Registrar and Share Transfer Agents or Depository Participants. The dispatch of these inland letters was completed on August 27, 2026, covering 3,069 consignments via Net Air Express Couriers.

Shareholders are advised to check their eligibility on the NSDL platform during the specified window to ensure their votes are recorded before the deadline.

Ishita Drugs and Industries Limited reported a net profit of ₹23.02 lakh for the quarter ended June 30, 2026, marking a decline from the ₹30.23 lakh earned in the same period of the previous year. The Ahmedabad-based pharmaceutical company’s revenue from operations fell sharply to ₹314.53 lakh in Q1FY26, compared to ₹540.05 lakh in Q1FY25. This contraction in top-line growth was the primary driver behind the lower profitability, despite a reduction in cost of material consumed. The Board of Directors approved the unaudited financial results on August 8, 2026, following a limited review by statutory auditors Jaymin Shah & Associates.

Beyond financial performance, the Board addressed key governance and operational matters during its meeting on August 8, 2026. The Board approved the re-appointment of Mrs. Abha Agrawal (DIN 01589479) as a Non-Executive Non-Independent Director, notwithstanding her attaining the age of 75 years. Her re-appointment is subject to shareholder approval at the upcoming Annual General Meeting. Additionally, based on recommendations from the Audit Committee and the Nomination and Remuneration Committee, the Board accepted the revised remuneration proposal for Mr. Sumit Agrawal, Chief Financial Officer.

The company is currently undertaking significant infrastructure upgrades to comply with Revised Schedule M regulations for its manufacturing facilities. Managing Director Jagdish Agrawal informed the Board that construction of a new block for warehouse accommodation has been completed, while civil work for extending existing buildings is ongoing. To date, Ishita Drugs has spent nearly ₹435 lakh on renovating existing buildings and constructing new blocks. Furthermore, capital contracts and orders worth approximately ₹565 lakh have been issued for various utilities and equipment. The company is actively negotiating with banks to raise funds to finance this upgradation project.

Financial Performance Breakdown

The financial results for Q1FY26 reflect a challenging period compared to the prior year, although there was a slight improvement over the immediately preceding quarter (Q4FY26). Total income stood at ₹318.16 lakh, down from ₹549.16 lakh in Q1FY25. Cost of material consumed decreased substantially to ₹138.45 lakh from ₹379.59 lakh in the previous year’s corresponding quarter, indicating better input cost management or lower production volumes. However, this saving was offset by the steep drop in revenue. Other income also contracted to ₹3.63 lakh from ₹9.11 lakh year-on-year.

What the Numbers Show

A notable divergence exists between revenue trends and expense management in Q1FY26. While revenue dropped by approximately 42% year-on-year, total expenses fell by roughly 43%, demonstrating effective cost control during a period of lower sales volume. Specifically, finance costs reduced to ₹0.47 lakh from ₹2.33 lakh in Q1FY25, contributing positively to the bottom line. However, other expenses remained relatively sticky at ₹72.70 lakh, only slightly higher than the ₹66.83 lakh recorded in Q1FY25, suggesting fixed overheads are not scaling down proportionally with revenue. The debt-equity ratio remains at 0.00, indicating a debt-free balance sheet, which provides flexibility for the planned facility upgrades without immediate pressure on interest servicing.